Real-World ALK TKI Outcomes in Metastatic NSCLC

Key Takeaways

• In a tertiary-center real-world cohort of metastatic ALK-rearranged NSCLC treated with ALK TKIs, long-term survival was substantial.
• Overall survival was longer with first-line alectinib than with first-line crizotinib in the reported cohort.
• Progression-free survival was longest with alectinib, intermediate with brigatinib, and shortest with crizotinib.
• ECOG performance status, histological subtype, and PD-L1 expression were independent prognostic factors for overall survival, and first-line lorlatinib showed a preliminary durability signal.

Metastatic anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) now has several ALK inhibitor options, but long-term real-world expectations remain less certain than trial results. Prognostic features and treatment-sequencing signals are also less well defined once therapy unfolds in routine practice. That uncertainty frames what investigators examined at a tertiary oncology center.

Investigators retrospectively analyzed 83 patients with metastatic ALK-rearranged NSCLC treated with ALK tyrosine kinase inhibitors (TKIs) at a tertiary oncology center. Survival outcomes, prognostic factors, treatment sequences, and adverse events were assessed with Kaplan-Meier estimates and Cox regression.

After a median follow-up of 69.4 months, median overall survival was 73.9 months (95% CI, 58.51-89.32) in the Cancers analysis of long-term ALK TKI outcomes. Among first-line regimens, median overall survival was 84.8 months with alectinib versus 63.6 months with crizotinib. These figures provide the main long-term survival benchmark from this cohort.

Median progression-free survival was 47.5 months with alectinib, 23.0 months with brigatinib, and 14.9 months with crizotinib. Eastern Cooperative Oncology Group (ECOG) performance status, histological subtype, and programmed death-ligand 1 (PD-L1) expression were significant and independent prognostic factors for overall survival. First-line lorlatinib had median progression-free survival not reached and a 24-month progression-free survival rate of 80%, while later-line lorlatinib retained activity; treatment-related adverse events were generally manageable.

These results are observational data from a single tertiary-center real-world cohort and should not be read as head-to-head proof between ALK inhibitors. The authors described the first-line lorlatinib signal as preliminary because the subgroup was small and follow-up was relatively short. The non-U.S. single-center setting also limits direct extrapolation to routine U.S. or North American practice.

Overall, the authors reported long-term real-world survival outcomes and prognostic information for metastatic ALK-rearranged NSCLC treated with ALK TKIs. ECOG performance status, histological subtype, and PD-L1 expression were the clearest independent prognostic factors for overall survival in this analysis. They also reported a first-line lorlatinib durability signal that requires longer follow-up.

Clinician Questions

How broadly do these ALK TKI outcome data apply in metastatic ALK-rearranged NSCLC?

These findings come from a retrospective single tertiary-center cohort of patients with metastatic ALK-rearranged NSCLC treated with ALK TKIs, so they provide real-world benchmark information rather than universal comparative estimates across all oncology practice settings or health systems.

What were the independent prognostic factors for overall survival measuring in this cohort?

The reported factors reflected patient functional status through ECOG performance status, tumor type through adenocarcinoma versus non-adenocarcinoma histology, and tumor biomarker status through PD-L1 expression.

How did the report distinguish first-line from later-line lorlatinib activity in metastatic ALK-rearranged NSCLC?

First-line lorlatinib was described as showing durable disease control, but the authors explicitly labeled that signal preliminary because the subgroup was small and follow-up was relatively short. Later-line lorlatinib was reported to retain activity after earlier therapy rather than appearing inactive once used beyond the first line.